[go: up one dir, main page]

WO2024257066A2 - Dispositif intelligent pour adapter numériquement l'état de consommation d'une substance - Google Patents

Dispositif intelligent pour adapter numériquement l'état de consommation d'une substance Download PDF

Info

Publication number
WO2024257066A2
WO2024257066A2 PCT/IB2024/055904 IB2024055904W WO2024257066A2 WO 2024257066 A2 WO2024257066 A2 WO 2024257066A2 IB 2024055904 W IB2024055904 W IB 2024055904W WO 2024257066 A2 WO2024257066 A2 WO 2024257066A2
Authority
WO
WIPO (PCT)
Prior art keywords
substance
patient
data
product
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/055904
Other languages
German (de)
English (en)
Other versions
WO2024257066A3 (fr
Inventor
Florian Enghard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2024257066A2 publication Critical patent/WO2024257066A2/fr
Publication of WO2024257066A3 publication Critical patent/WO2024257066A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
    • A24F40/00—Electrically operated smoking devices; Component parts thereof; Manufacture thereof; Maintenance or testing thereof; Charging means specially adapted therefor
    • A24F40/65—Devices with integrated communication means, e.g. wireless communication means

Definitions

  • the present invention relates to a smart device for digitally adjusting the state of a substance to be consumed and to a corresponding method.
  • One of the preferred substances for the purposes of the present invention is cannabis, especially medical cannabis.
  • Medical cannabis can be used for various conditions, especially in cases where conventional medications do not help patients sufficiently or in cases of serious side effects. Scientific studies show that cannabis does not cure any disease or illness, but it can alleviate symptoms or inhibit the development of a disease. Based on randomized, double-blind, controlled clinical data, cannabinoids have been shown to be therapeutically effective in chronic pain, multiple sclerosis, nausea, vomiting and appetite, Gilles de la Tourette syndrome, glaucoma.
  • Cannabinoids also show promising results in the symptomatic treatment of hyperactivity, anxiety and allergies. In addition to medical treatment, patients often experiment with self-medication in various forms. Cannabis is used for conditions such as anxiety, cancer, epilepsy, inflammatory bowel disease, Parkinson's disease, psychiatric disorders, insomnia/sleep disorders, hyperactivity, anxiety disorders and allergies.
  • Dosage varies from patient to patient. It is important that dosage is titrated (increased) slowly, regardless of the product. The focus is on determining the right dose for each individual patient in order to really reap all the benefits of medical cannabis. It is better to take several small doses throughout the day that will achieve the desired result overall, rather than experimenting with a high dose. Cannabis can have different effects from patient to patient. You should wait until the effects occur (or not). It is best to use the same (low) dose for several days and monitor the effects
  • the patient can increase the dose, but only slowly. Wait a few days after each dose increase to determine progress. Within about one to two weeks, patients should be able to determine their own personal dose that produces the greatest medical effect with minimal side effects.
  • overdose By establishing a treatment protocol, overdose can usually be avoided. If a patient takes too high doses of THC, the side effects mentioned above may occur.
  • Undesirable side effects and risks occur primarily after consuming high doses or when medical cannabis is consumed in combination with other substances that enhance the effect, such as certain medications. When administered correctly, medical cannabis has no identified toxic effects on the health of patients.
  • the common acute side effects of high doses of cannabis occur very quickly after consumption and include increased heart rate, reduced blood pressure, dizziness, dry mouth, red eyes, increased appetite, mild euphoria (avoid drug high), reduced alertness after consumption.
  • Smart device for digitally adjusting the state of a substance to be consumed, comprising a device for receiving an inserted substance to be consumed, which is designed to bring the substance into a consumable state, in particular an aggregate state, whereby the substance to be consumed can be identified by the device through a sensory feature, such as a QR code or a sensor chip.
  • Smart device wherein the device is connected to a mobile unit, such as a smartphone, which is designed to retrieve data and/or instructions stored for the substance to be consumed via an app or access to a cloud and to execute them via a digital connection to the device.
  • a mobile unit such as a smartphone
  • Smart device according to item I or II, wherein the device and/or the mobile unit is connected to a body-worn device, such as a smart watch or the like, wherein the body-worn device is designed to record physical and/or physical and/or chemical data of a person wearing the body-worn device, to compare them with the stored data and/or instructions and to interact based on the comparison.
  • a body-worn device such as a smart watch or the like
  • the body-worn device is designed to record physical and/or physical and/or chemical data of a person wearing the body-worn device, to compare them with the stored data and/or instructions and to interact based on the comparison.
  • Multi-evaporation device comprising a device for evaporating a vaporizable substance and a receiving device for substance containers, wherein the receiving device is designed to receive at least two substance containers simultaneously, which can be alternately connected to the device for evaporation.
  • Multi-evaporation device according to item V, wherein the receiving device is designed like a revolver.
  • Multi-evaporation device wherein the receiving device is designed like a magazine.
  • Multi-vaporizer according to item IX wherein the first carrier for flavors and the second carrier for flavors are separate from each other, preferably in two separate components.
  • Multi-vaporizer according to item IX or X wherein the second carrier is positioned so that the created vapor mixture can mix from the aroma from the first carrier and the second carrier.
  • the present invention relates to a smart device for consumer-specific adaptation of the consumption of substances, comprising a device for receiving, identifying and processing an inserted substance to be consumed, at least one inserted substance to be consumed which is clearly identifiable by a sensory feature such as a QR code or a sensor chip, at least one mobile unit worn by the consumer and/or close to the body, at least one wireless network communication between all units worn by users, at least one wireless network connection to a central or decentralized data server for exchanging the data recorded by the consumer, at least one interface for medical professionals for assessing the data recorded by the consumer.
  • a smart device for consumer-specific adaptation of the consumption of substances comprising a device for receiving, identifying and processing an inserted substance to be consumed, at least one inserted substance to be consumed which is clearly identifiable by a sensory feature such as a QR code or a sensor chip, at least one mobile unit worn by the consumer and/or close to the body, at least one wireless network communication between all units worn by users, at least one wireless network connection to a central or decentralized data server
  • An alternative embodiment relates to a smart device for digitally adjusting the state of a substance to be consumed, wherein the device for receiving an inserted substance to be consumed is designed to bring the substance into a consumable state, in particular an aggregate state, and is identifiable by the device through a sensory feature, such as a QR code or a sensor chip.
  • the smart device is connected to a mobile unit, such as a smartphone, which is designed to retrieve data and/or instructions stored for the at least one substance to be consumed via an app or direct access to a central or decentralized data server and to execute these via a digital connection to the device, as well as to send data obtained via the mobile unit worn close to the body to the central or decentralized data server.
  • a mobile unit such as a smartphone
  • the substance to be consumed can be released by medical professionals in predefined quantities, units or time periods, whereby the active ingredient concentration and the amount of active ingredient released can be regulated by setting the temperature or using a nebulizer unit, and the absorption can be monitored by monitoring the inhalation behavior (duration, depth).
  • the smart device according to the invention can further be designed in such a way that the data obtained by the body-hugging unit and sent to the central or decentralized data server via the mobile unit, such as the smartphone, can be processed there and compared with consumer-specific data typical of the disease or scientific study databases in such a way that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of at least one substance for preventing or alleviating acute attacks of the disease, in a temporally close connection with the data collected.
  • the data obtained by the body-worn unit and sent to the central or decentralized data server via the mobile unit, such as the smartphone can be processed there and compared with consumer-specific data typical of the disease or scientific study databases in such a way that the consumer receives a recommendation via the mobile unit, such as the smartphone, with information on the dosage and type of at least one substance to prevent or alleviate permanent disease patterns, in a closely temporal connection with the data collected.
  • the two aforementioned alternatives can be developed in such a way that the consumer receives the recommendation with information on the dosage and type of at least one substance at fixed time intervals.
  • a second aspect of the present invention relates to an aerosol-forming device comprising a device for converting at least one substance into an aerosol or a state of aggregation, a receiving device for substance containers, wherein the receiving device is designed to receive at least two substance containers simultaneously, which can be alternately connected to the device for vaporization.
  • the device for converting a substance into an aerosol or a state of aggregation is the device for receiving an inserted substance to be consumed, as described above.
  • the receiving device for substance containers is designed like a revolver drum and the fill level can be displayed either directly on the substance container or via a display on the aerosol-forming device or via an app.
  • Another alternative is an aerosol-forming device in which the receiving device is designed like a magazine and the fill level can be displayed either directly on the substance container or via a display on the aerosol-forming device or via an app.
  • a special embodiment provides that the aroma to be vaporized can be selected from the at least two substances in the magazine, using the revolver drum-like mechanism.
  • the substances can be mixed with one another in a freely selectable ratio controlled mechanically by the consumer or digitally via the app before they are vaporized from a collecting container provided for this purpose, and that they can be processed from at least two substances in a temperature-specific manner by several steam generators within the aerosol-forming device and a consumer-specific steam mixture can be set.
  • composition of at least two substances mixed together can be stored at least on the smartphone or on the central or decentralized data server and can thus be accessed by other consumers at any time.
  • aerosol includes smoke, vapor, mist, which can be created by evaporation, combustion, etc.
  • the substances to be consumed can be in various forms, such as solids, ground solids, liquids, liquids, oils. Solids are usually burned, liquids are usually vaporized. The above conversion of these substances into a suitable state of aggregation is carried out using an aerosol-forming device.
  • A1 is a vaporizer and A2 is a VAPE PEN.
  • A1 is a vaporizer and A2 is a VAPE PEN.
  • A1 is a vaporizer and A2 is a VAPE PEN.
  • A1 is a vaporizer and A2 is a VAPE PEN.
  • These have a QR code reader/device in which the white.
  • identification could take place via sensor technology such as a chip RFID or similar.
  • a cartridge/tank is displayed, which is preferably but not exclusively already full.
  • This tank has a QR code or a chip or similar sensor devices attached so that the reader in A1 and/or A2 can identify it. Since the vaporizer is battery-operated, consumption can be blocked via the QR code or the RFID CHIP or similar by not activating the battery or the vaporizer function. This could be the case for the following scenarios, for example but not exclusively: the insertion of an incorrect product, a ban, a medical order or similar.
  • A is connected to an app using a mobile device (tablet, mobile phone), preferably via WLAN/Bluetooth or similar.
  • a mobile device tablet, mobile phone
  • Information is stored about the medical findings, any instructions from the attending physician, medical instructions, dosages.
  • A indicates the physician or medical facility that can enter and optimize orders via the cloud or access to the patient’s app. These are stored as an arrangement on the mobile app (B), in a cloud (C) or directly on the vaporizer (C) (vaporizer / PEN).
  • the possible deposits are made under D1 for the order of medicine (e.g. cannabis variety, CBD variety, THC content)
  • medicine e.g. cannabis variety, CBD variety, THC content
  • the dose is stored with the number of puffs that can be measured using device C.
  • alarm devices can be installed which, for example, indicate a rapidly rising blood pressure, this is just an example of the possible display via a smart device/smart watch
  • A defines the user or doctor who can attach or prescribe a smart watch for self-monitoring or for monitoring by the doctor.
  • the doctor can monitor and adjust prescriptions and set the medical prescription based on the feedback of the physical, physicochemical and/or chemical data via the smart watch B and/or via a patch C for blood testing, etc.
  • the monitoring under B and C can be recorded at the same time as consumption, which is communicated digitally, via the vaporizer to the smart watch and/or the cell phone/app.
  • This allows the medicine to have a direct effect on the physical, physicochemical and/or chemical data.
  • parents, a third party, a government or medical institution are listed under A. These can use the app to enter information and instructions about the THC content, amounts and time of consumption. Prohibitions are also possible.
  • the mobile unit/mobile device or cloud C
  • the GPS shows whether you are in a prohibited zone. If the person is in a prohibited zone, consumption is not possible. Free zones are recommended.
  • the prohibitions, information on the content, quantity and time are passed on to the vaporization devices (D) via the mobile device or via the cloud.
  • the information stored on consumption via the vaporizer is also related to and set for specific products in relation to the optimal temperatures.
  • This information is also stored via the QR code/sensor chip, which communicates with the vaporizer by inserting or scanning the packaging. It is also possible for the consumer to set temperatures to reduce or increase the effectiveness.
  • the doctor could store this information and, for example, allow three puffs at a temperature of 150 °C and only allow two puffs at a temperature of 180 °C, which increases the active ingredient content (by “puffs” we mean breaths/inhalation).
  • the doctor (D) has the option of prescribing and determining medication based on the patient (A) information and the patient findings (A) and of checking and monitoring this as well as the patient's physical/chemical data.
  • the doctor (D) prescribes a product/medicine (F) based on the findings, which is identified by an identifying feature, for example a QR code. Code and/or a chip.
  • the patient (A) is prescribed or provided with a vaporization device (B2, B3) such as a pen or a vaporizer. These devices (B2, B3) can be identified using a device ID.
  • a mobile device (B1) such as a tablet or a cell phone, via Bluetooth, WLAN or similar.
  • the prescribed dosage and intake of the medicine as well as the dosage specifications are passed on to (B) via the cloud (G).
  • the vaporization devices (B2, B3) have a reader (X) to read the QR code and/or RFID chip (F1) attached to the product (F). Verification could also take place via a mobile device (cell phone, tablet/B1). Using the reader installed in the vaporizer (or the mobile device B1) and the identification feature attached to the product/medicine (QR code/chip F1), the device (B3, B2) can recognize the medicine/product (F) used and assign it to the patient using the device ID. The device then follows the instructions/application/order of the doctor (D) via access to the cloud (G). The stored medical order such as dosage, time of application, etc. are implemented by the vaporizer device (B) only functioning in accordance with the application instructions specified by the doctor. The device is also programmed in such a way that it is preferably not functional if other cartridges and/or unknown QR codes/chips are inserted.
  • C1 is a smart watch, C3 a smart belt and C21 a smart patch. These devices are intended to be worn by the patient in order to measure physical and chemical data as well as data from the environment.
  • These devices under (C) are in turn connected to the devices (B) via digital connections such as Bluetooth, WLAN or similar. This means that there is a clear connection, particularly in terms of time, between the consumption of the medication by the vaporizer (B) and the physical and chemical patient data (C) measured by the devices C1, 2, C3.
  • the doctor (D) can track this data precisely and evaluate it in statistics. He also has the option of intervening directly in consumption and storing a new medication, consumption order, etc. for the product and the vaporizer via the cloud (G) using the patient's identification features.
  • Figure 394-1 The doctor (F) enters the patient (A1) and his patient information (A2) into the digital cloud/app/server etc.
  • the patient (A1) is assigned a vaporizer (B1), which can be assigned via a device ID.
  • This device can optionally be connected to a digital device (tablet, mobile phone, location-based error, etc.) via Bluetooth/WI_AN etc. or similar.
  • the information about the product is assigned using a QR code/RFID (preferably via cloud access).
  • QR code/RFID chip Based on this information stored via QR code/RFID chip, the vaporizer can use its integrated reader (QR code, RFID) to assign the information about which medication it is and, in conjunction with the vaporizer ID, also implement the patient data and the doctor's instructions.
  • the doctor selects the various ingredients (C1), which are readable by QR code/RFID attached to the product.
  • the selection is made according to the patient's diagnosis (C2) and/or according to the production information (C3).
  • the patient (A1) is provided with a measuring device (D2) which carries out measurements (physical and/or chemical) and transmits them to the cloud (E). These measured data are defined over 24 hours, but also at the time of consumption and the amount consumed.
  • the doctor (F) can then view these in the cloud (G) and adjust, optimize, restrict and block the medication.
  • Production C3 has the option of blocking batches in the event of recalls by entering the information in the cloud (E) and the read QR code/AF ID in the vaporizer no longer works.
  • an alarm message can be sent via the connected device (D).
  • the doctor (11) creates the patient (A) with all possible patient data, history as well as origin etc. (A1) After the patient (A) and his diagnosis (A1) have been created, the doctor prescribes his medical order according to the present invention (this could be done by setting time for inhalation, pause between inhalations, time settings for the day and temperature for combustion in the vaporizer. The doctor could also simply set the dose and then issue recommendations for consumption based on the data collected in the cloud.
  • a smart device such as (smart watch, smart patch, smart belt) to measure the physical and chemical data of the patient and his environment.
  • the patient (C) receives his prescribed medicine according to the present invention based on his patient information (A) and his findings (B).
  • D2 D3 D4 he is ordered to be monitored by various devices (smart watch, smart patch, smart body world or similar).
  • these devices measure data (E) such as (E1) physical, (E2) chemical data of the patient as well as (E3) data of the environment.
  • E1 blood pressure, body temperature, tremors or similar could be measured.
  • E2 blood values, oxygen levels, THC/CBD levels or similar could be measured.
  • E3 the location and thus the weather conditions, temperature, humidity could be measured via GPS.
  • information such as the order of new medication, change in diet, new clinical picture and E3 could be included for comparison with the data according to E.
  • the cloud (A) communicates with the vaporizers (E) and the digital devices connected to them (mobile phone, tablet or similar).
  • the doctor (C) transmits his prescription/order to the cloud, which can be assigned to the patient via the ID of the devices (E) and the prescribed medication, which can be recognized and defined via the QR code/RFID verification between the product/inserted cartridge and the reader of the vaporizer.
  • Access by the vaporizer or the mobile device (E) connected to the vaporizer enables the prescribed medicine, dosage, etc. to be implemented via the doctor (C) and his patient-related data to the cloud (A).
  • the medical prescription could be followed under (F) using information about the product stored in the cloud (A), with the vaporizer (E) implementing the dosage accordingly.
  • Measuring devices attached in or to the body (A1, an implanted chip, A3 a smart watch or a body belt, A3 a smart patch for measuring blood count and ingredients.
  • All of this input data would be assigned to the product/medicine as well as the doctor’s prescription via the QR code/chip and to the associated vaporization device, assigned via the device’s ID.
  • An optimal setting for dosing could use algorithms based on the plant/product (A), the vaporization temperature (B) and the number or duration of puffs taken by the patient/consumer. All three components (A, B, C) affect the dose that the patient/consumer takes.
  • D1 a plant is burned at 150 °C and inhaled with three puffs of 2 seconds each, resulting in the dose ABC.
  • the doctor could prescribe medicine (C) and medicine 2 (C1).
  • the vaporizer or device A such as a mobile phone connected to the vaporizer (A1), can assign the product.
  • the doctor can store the medication and dosage in the cloud, product-specific and assigned to the patient.
  • the application could be implemented in a patient-oriented manner, whereby the patient is informed about consumption and breaks through sound or vibration, or light effects such as a green light or red light. This could also take place via the mobile device, preferably even via voice messages or accompaniment. In case of recall via production, this product-specific via the QR code/chip could function via alarm functions and information via the mobile device.
  • F1 one pull 2 seconds, 3 minutes break.
  • F2 one pull for 2 seconds, 3 minutes break.
  • the patient (G) is monitored in parallel with these applications (D) (E) (F) in terms of his physical and chemical data (smart watch, smart belt, smart patch or similar). This information would be passed on to the cloud and accessible to the doctor. The doctor could monitor and adapt his applications D, E, F.
  • the present invention is additionally described in the further figure S 16.
  • the vaporization device which includes a reader in addition to the vaporization function to identify the product under A1 as well as to identify at least one person in order to enable the product information and dosage stored for the product and for the person (A1) as indicated under A2.
  • the information for A is stored under B, one steals, which is fed with various information about the patient B1, about the product/dosage B2, consumption when and what dosage B3, if applicable as specified under B4 weather conditions, which could affect the physical and/or chemical data of the patient, also under B4 possible arrangements or new regulations. Possible exclusion zones could also be set up in which consumption is not permitted
  • C2 could be a device such as a smart watch, a measuring device in the form of a belt, an RFID chip, a functional patch or similar.
  • the doctor prescribes a vaporizer for the patient, which is assigned to the patient by the device ID.
  • the device also has a sensor reader, which can use sensors to define the cannabis medicine used using a sensory identification feature (RFID/QR or similar).
  • RFID/QR sensory identification feature
  • This device is connected to a cloud. The doctor can thus prescribe all medically necessary parameters and monitor and control the therapy. To prevent misuse, the device can also be assigned to a specific patient.
  • the number of puffs, breaks between puffs and intakes, or even the vaporization temperature for the medical cannabis can be controlled.
  • the patient is provided with at least one measuring device in the form of a body belt, a smart watch, or a needle patch. These are linked to the device ID and thus to the patient.
  • the doctor thus knows in detail how the patient reacts to the respective consumption. He can adjust the parameters accordingly in order to set up an optimal therapy for the patient with as few side effects as possible.
  • the monitoring also provides excellent protection for high-risk patients such as those with high blood pressure or heart problems.
  • the doctor can intervene immediately or set the device to switch off at a predefined value and the patient cannot use it for the time being.
  • indications and dosage can be improved and contraindications and risk factors can be avoided.
  • the doctor can benefit from the project by participating in studies.
  • the device according to the invention is in particular a medical application device which is assigned to a patient via a device ID and which gives the doctor the opportunity to monitor and adjust the patient's dosage via a cloud. Simultaneous monitoring of the patient's physical and chemical data is optionally possible via another measuring device assigned to the patient.
  • a medical application device which is assigned to a patient via a device ID and which gives the doctor the opportunity to monitor and adjust the patient's dosage via a cloud. Simultaneous monitoring of the patient's physical and chemical data is optionally possible via another measuring device assigned to the patient.
  • Two alternative vaporizers are shown under A and B. Both vaporizers have the option of accommodating multiple product cartridges, i.e. devices for vaporizing a vaporizable substance.
  • a revolver device is described under 1.
  • B1 a plug-in device with the option of plugging in at a specific time is shown.
  • the selection for vaporizing the products used could work through a viewing window and manually by pressing a button or some kind of revolver device in the actuation. These would be physical devices and activation of the vaporization.
  • Figure 2 shows, on the one hand, under A and B, the physical activation with the already described rotating mechanism according to a revolver under A1. Under B2, the selection of products in the (magazine-like) plug-in device would be activated with button activation mechanisms.
  • These versions are merely examples.
  • the basic idea is to be able to insert at least two cartridges (E) into a vaporization device and activate them for vaporization as selected.
  • the vaporizer is connected to a mobile device (tablet, mobile phone or similar).
  • the data stored in the vaporizer inserted product cartridges would be displayed on the mobile device display (C/D).
  • the identification of the inserted product cartridges (E) would work via QR code or RFID CHIPS attached to the product cartridges, by installing a dedicated reader (A2) in the vaporizer device, which can identify the inserted products. These digitally identified products are then preferably communicated to the mobile devices (tablet, mobile phone) (C/D), preferably via the device ID of the vaporizer device. This gives the user the option of mixing different active ingredients, flavors, vitamins, THC and CBD varieties, selectively switching them on, and adjusting the percentage for each active ingredient.
  • Sketch D shows an evaporator which is provided with a reader (D1, D2, D3) for the identification features (ABC) which are attached to the product cartridges (A, B, C).
  • the vaporizer D is connected to the mobile devices via Bluetooth, WiFi or similar.
  • An app and/or a cloud now offer the digital option of activating various products/product cartridges on the display (E).
  • a B C is shown on the display, these are the cartridges (A/B/C) inserted into the vaporizer device (D) read by the reader (D1/D2/D3) and digitally communicated to the mobile device (E).
  • the cartridges A/B/C
  • D the cartridges
  • D1/D2/D3 the reader
  • E it is possible to activate or block product cartridges.
  • E1 there is a digital option via display to enter percentage settings for each product cartridge used.
  • E2 there is a warning / alert under C. This could be a recall from the manufacturer or a defect in the cartridge.
  • a saving button can be pressed to save the selection.
  • the selection of the cartridge, the combustion, the percentage or similar is then saved in a saving list Consumption could also be measured digitally with at least one cartridge. If several cartridges are consumed, the consumption would be added together. Preferably, but not exclusively, the following would be measured: duration of consumption (e.g. 1.2 hours / day 1, 35 minutes day 2), amount of active ingredients consumed (THC, nicotine, shisha vape vapor, vitamins & minerals, etc.).
  • Monitoring for smoking cessation could also measure and monitor the duration of consumption or consumption of the active ingredients, and optimize or adjust the data if necessary (blocking, restricting, specifying amounts and times, etc.). Measurements of the legal maximum consumption could also be taken and compared with the requirements of the respective country/location.
  • E5 shows possible tank readings for each cartridge.
  • E6 offers the option of reordering and paying for tank information that is empty or close to empty online.
  • the vaporizer A is connected to a mobile device (A1) / mobile phone / Tablet or similar connected via Bluetooth, WiFi or similar.
  • the doctor (C) prescribes a THC cartridge based on a medical diagnosis, preferably several, but these are adapted to the diagnosis.
  • the doctor could preferably store the dosage in the cloud and a better result could be achieved by mixing different plant extracts.
  • E Automated settings are also possible under E. These would include, for example, selecting places where smoking is not allowed.
  • time setting can be set for each product. For example, medication, cannabis plants that are activated should not be smoked in the evening. They can also be blocked in the event of excessive consumption.
  • a (A) the vaporizer accommodates various product cartridges (B 1, 2, 3, 4) in its receptacles (A 1, 2, 3, 4), preferably ordered by the doctor. As already described, these are read by a reader using their identification feature and then communicated digitally via WLAN and/or Wi-Fi to a mobile device and/or to a cloud (F).
  • the doctor (E) preferably stores an order for the medication and its intake in the cloud (F).
  • the cloud (F) communicates this to the vaporizer (A) (preferably via mobile device).
  • the device (A) is assigned to a patient by its device identification number. This allows the doctor to store different mixtures and instructions for consumption in the cloud, specific to the patient and the product.
  • the arrangements (D) are implemented digitally and preferably monitored weekly and also changed if necessary.
  • C1 and C2 one product cartridge is released for consumption each week.
  • G This is monitored by measuring devices that can be assigned to him and the vaporizer device. These are a smart watch, a body belt, a smart patch, but not exclusively. These devices measure chemical and physical data in the patient both at the time of consumption and over the course of the day. Furthermore, the patient communicates with the doctor about his well-being and the effect. This could also be implemented instead of a personal conversation with a digital questionnaire, preferably with a well-being points program.
  • the doctor (E) has the option of changing the application, for example in the form of number of inhalations, time of inhalation, temperature of the vaporizer during inhalation, breaks between inhalations, daily application, type of active ingredient.
  • the second aspect of the present invention is supplemented by a sub-aspect relating to a multi-vape, i.e. a vaporization device for multiple substances.
  • vape devices for vaporizing nicotine-containing and non-nicotine-containing substances that are chemically enriched with flavors for better taste.
  • the market is divided into single-use and multiple-use vapes.
  • the ingredients to be vaporized are applied to a carrier material. This consists of glycerin, propylene glycol and nicotine (also available as a nicotine-free version). Flavorings are also added.
  • flavours could be stored at different temperatures Prerequisites for the best consumption taste.
  • the consumer does not have the opportunity to actively change the taste.
  • the present invention aims to solve this problem and to make an active change that is possible at any time.
  • the first carrier is preferably for glycerin, propylene glycol and possible nicotine enrichment
  • the other second carrier is enriched with the flavors
  • the aroma carrier is interchangeable in the embodiments according to the invention. This could be possible with plug-in devices on the top, bottom or side.
  • the plug-in devices could also be used to create multiple, interlocking, freely selectable variations of aromas.
  • the strength of the aromas could also be adjusted using manual or digital devices. This could, for example, be regulated by the size of the draft inlet of the aroma carrier.
  • Figure 451-6 in A shows another way of providing multiple flavorings via carrier materials.
  • carrier 1 is shown with glycerine, propylene glycol and nicotine. This is heated by a battery-powered mechanism via electrical devices.
  • D, D1 and D2 the carriers are shown exclusively for the flavors. These preferably but not exclusively (shown here as an example) have their opening on the top through which the aroma can escape and combine with the vapor mixture from E.
  • the openings C, C1, C2 can be manually or digitally adjusted in their ventilation flow.
  • a medicament preferably a herbal, cannabis, powder product, either ground or in a liquid form.
  • This product is attributed to a device that preferably receives information about the product properties of the product used via a database in order to then adjust the vaporizer/smoking device.
  • the temperature and/or the permitted air flow for consumption is regulated here.
  • a temperature is set for vaporization/combustion, with knowledge of the release of the active ingredient of the product used at the temperature used.
  • the dosage is carried out with knowledge of the active ingredients released, which can be dosed in an adjustable air flow/inhalation of the consumer/patient.
  • 1 denotes the patient who is communicatively connected to the doctor 10 via a database/cloud.
  • the doctor 10 creates the patient under 8 with his age, gender, medical record, diagnosis and prescription or similar/other.
  • the database also contains general information about the product information/medication/active ingredient, the product properties, particularly in combustion/evaporation and percentage release of the active ingredient in the form of vapor/smoke/aerosol/mist.
  • the patient receives a vaporizer/smoking device under 3.
  • This device is provided with an ID that is assigned to the patient and identifiable by the database.
  • the connection to the database 5 can be direct or via a mobile device (mobile phone/tablet), preferably via an app to the database.
  • At least one product cartridge 2 is assigned to the vaporizer / smoking device 3.
  • the patient also receives a measuring device 4, which monitors the patient's physical and chemical data. These are passed on to the database in real time or at frequent intervals. This enables monitoring 11 as well as early warning signals, measured chemically and/or physically on the patient, which then communicate medication to the patient preferably via vibration, sounds or similar via the mobile devices. In this way, intake, consumption/medication can be recommended early based on the early warning signals measured by the measuring device 4.
  • the dosage for the product 2, consumed via the device 3 is stored by the doctor 10 in the database 5, this also applies to the prescribed product under 6.
  • the dosage is implemented by knowing the general information 6 and setting in relation to the combination of the product 2 and the combustion / vaporization in the vaporizer / smoking device 3.
  • the data on the product and the vaporization of the product under a certain temperature are stored here.
  • the dosage is thus given according to the release of the active ingredient above a certain temperature, these temperature-regulated releases are already known on the market through vape devices as well as vaporization devices.
  • Another aspect of the dosage is the adjustment of the air draft / air flow. This is preferably set according to air flow systems known on the market, which Regulate airflow by adjusting the top opening of the mouthpiece and/or the bottom of the airflow inlet, this by adjusting the openings through which the airflow passes.
  • the patient is monitored for 24 hours, as well as before, during and after consumption. This allows early warning signals about consumption to be communicated, as well as subsequent adjustments to the medication.
  • two or more product cartridges under 2 can be inserted into the vaporizer 3. This has the advantage that preferred/recommended combinations for consumption in the database are useful for the medication. For example, double indications in the diagnosis can be treated. For example, Tourette and insomnia. These two findings can be combined with a combination in the evening before going to bed, for example.
  • multiple, different strands in their combination can achieve a better effect, or the same effect but with fewer side effects, since the dosages for each medication / active ingredient are kept lower, but as a whole (combination of three active ingredients, each one third, for example) guarantees the same development / symptom treatment.
  • Figure II describes the focus of the dosage / dose 4.
  • the dosage / dose 4 is determined by setting various parameters such as
  • the air flow 3 can be adjusted in such a way as to offer a fixed active ingredient proportion for consumption.
  • the setting of the air flow is the length in unit of time, the active ingredient proportion in the air flow and the associated consumption of the known active ingredient proportion, the concentration of the active ingredient (vapor/smoke formation/aerosol and known active ingredient proportion).
  • the information about the product, product property 1, the information about the active ingredient release and vapor/smoke/aerosol formation for defined temperatures 2, as well as the definition of the air flow/draft created 3 are stored in the database.
  • the vaporizer/smoking device is connected to the database directly or via a mobile phone 6.
  • the reader in the vaporizer/smoking device reads the product cartridge (QR code, RFID or similar) and can use all the stored information (1, 2, 3) to implement the dosage information stored by the doctor in accordance with the invention.
  • FIG II 1.1 various product cartridges are shown under 1.1. These are preferably but not exclusively filled with the same amount of active ingredient. Furthermore, a sensory identification feature is attached to cartridges A/B/C. This is preferably but not exclusively in the form of an RFID chip or a QR code. These three cartridges A/B/C are then inserted into a vaporizer. This vaporizer reads the sensory feature and can access the database and process the information stored for this product cartridge and this vaporizer. On the one hand, this is the time of consumption. Here is an example A1/B1/C1/ consumed at intervals of 6 hours each, 9:00 a.m. / 3:00 p.m. / 9:00 p.m. In case study 1.1/1.3, the entire fill level is used up.
  • the fill level is also consumed at a preferred temperature that is recommended for the product.
  • CBD at 180 °C
  • THC prefers 170 °C.
  • the times of administration are specifically designed by the doctor for the diagnosis and the patient.
  • the database uses data entered into the database when creating the prescription and administration instructions. This data provides information about the diagnosis of the disease and the dosage to alleviate or eliminate the symptoms.
  • the interval between the times of taking the medication is set and the patient is informed, preferably via a signal, preferably vibration or sound, that he or she needs to take his or her medication again.
  • the intervals here are 6 hours as an example, with 2.5 mg of active ingredient (e.g. THC) each time and can be adjusted depending on the patient, diagnosis and clinical picture.
  • product cartridges with more active ingredient can be prescribed or the existing product cartridges can be consumed at a shorter interval, for example 4 hours instead of 6 hours. This increases the dose present in the blood.
  • the vaporizer gives a signal to take the drug at 9:00 a.m., 3:00 p.m., 9:00 p.m.
  • the entire amount of the active ingredient in the product cartridge is released.
  • the amount released is 2.5 mg.
  • Mr. Müller's pain has lessened, but he still feels slight pain. Mr. Müller's dosage is now being adjusted by the doctor.
  • Mr. Müller now receives 5 mg three times a day at 9:00 a.m., 3:00 p.m. and 9:00 p.m. These product cartridges, each containing 5 mg, are made available to Mr. Müller ready for consumption.
  • Mr. Müller always gets very tired after taking 5 mg.
  • the doctor prescribes Mr. Müller 2.5 mg but shortens the intake times by 2 hours.
  • Mr. Müller consumes more cartridges at 9:00 a.m., 1:00 p.m., 5:00 p.m. and 9:00 p.m.
  • a vaporization device is shown that can only hold one product cartridge.
  • several product cartridges can preferably be prescribed to the patient and when the signal is given, the patient can insert the product cartridge with the precisely defined amount of active ingredient and smoke.
  • a product cartridge with more active ingredient can also be used.
  • the dosage for the patient is delivered as prescribed and stored in the database via the vaporization device and the product cartridge used.
  • a vaporizer with at least two chambers for product cartridges is shown.
  • the vaporizer can read each chamber with a sensor reader using the sensor feature attached to the product cartridge (RFID chip/QR code).
  • the information about the product cartridge and active ingredient and product properties 2.1 are stored in database D.
  • the database communicates the stored data on the products, the product properties and the consumption instructions (vaporization temperature, duration of vaporization, airflow setting, preferably but not exclusively specifically designed for the product properties) to the vaporizer device.
  • THC burns best between 170 °C and 210 °C. This temperature defines not only the amount of active ingredient released, but also the ingredients that are released. There are various active ingredients here.
  • CBD only starts to release its active ingredient at 180 °C. If you want to add a flavor for taste, it depends on the flavor in question, but these usually burn best between 50 °C and 100 °C, but this is not the only temperature.
  • the information is stored in the database.
  • This information for the best development, effectiveness of the active ingredient and the taste, as well as the stored dosage instructions, are passed on to the vaporizer.
  • the vaporizer knows which product cartridges are used via the sensory characteristic on the product cartridge through the reader installed in the vaporizer. The vaporizer can thus use this stored information for each product cartridge in the Temperature, in the air flow, in the duration of evaporation / combustion as deposited.
  • THC Trigger's syndrome
  • CBD Trigger's syndrome
  • THC Tetrahydrofuran
  • the product cartridge with THC which is attributed to Mr. Müller, is instructed in the vaporization council via the database to burn at 210 °C.
  • the combustion time and the air flow are adjusted so that the stored amount of the active ingredient is released.
  • a CBD cartridge is also used, for which a temperature of 180 °C is stored.
  • the dosage setting for the vaporizer is also stored using the data stored in the database about the product, the air flow, the temperature.
  • Mr. Müller takes 10 mg of THC and 15 mg of CBD before going to bed.
  • the product cartridges vaporize independently and autonomously according to the instructions in the database, but are preferably but not exclusively consumed as a vapor mixture. This could be implemented via an intermediate chamber between the product cartridge and the outlet of the mouthpiece to the consumer/patient.
  • the product cartridges A1, B1, C1 can be inserted into any receptacle.
  • the vaporizer uses a reader to identify the sensory feature attached to the product cartridge.
  • the vaporizer has knowledge of the product, the product information and the stored product properties via the database, particularly in the consumption, vaporization and combustion and release of the active ingredient.
  • the database contains the temperatures that are best suited for vaporization and/or combustion of the respective products/active ingredients/flowers/aromas. These can be aromas that develop their aromas best at a certain temperature. These can be recommended temperatures for CBD and THC in order to best release the active ingredient without burning the product. For THC in particular, there are different temperature settings that release different active ingredients. This is particularly important in the medical field and is crucial for the correct setting and medication for the diagnosis.
  • Mr. Müller has a THC cartridge A, which is vaporized at 170 °C in the receiving chamber A1, a CBD cartridge B, which is vaporized at 180 °C in the receiving chamber B1, and the product cartridge C, which is filled with aroma, which has the aroma development without burning at 70 °C.
  • the information about the vaporization temperatures for the respective products is stored in the database.
  • the THC range it is from 170 °C to 210 °C, CBD from 180 °C and flavors mostly under 100 °C.
  • Mr. Müller can also mix products together himself, improving the taste with active ingredients and flavors. By adjusting the air flow and/or the temperature, Mr. Müller can also dose the various product cartridges used via the vaporization device and, if necessary, save them via the database/app.
  • Patients can therefore assist Mr. Müller, if necessary or in study programs, by increasing or decreasing their settings depending on their well-being and symptom relief and saving the desired result. This can also be done in collaboration with the doctor.
  • Figure V.4 describes a vaporizer.
  • the active ingredient content under 4.2 is shown as 0%.
  • Under 4.1 a maximum value is set which should not be exceeded.
  • This information is stored in the database, access to the database is via the vaporizer or via a mobile phone / tablet or similar that connects the vaporizer to the database.
  • the mean value is a percentage of the active ingredient that alleviates or eliminates the patient's symptoms.
  • Mr. Müller receives dose 1 at 9:00 a.m. Through inhalation, the effect takes effect after 20 minutes and lasts for around 4 hours. After three and a half hours, the effect wears off. At 1:00 p.m., after 4 hours, dose 2 is consumed. This increases the dose again within 20 minutes and lasts for a further 4 hours. A dose is released at 5:00 p.m. Through frequent intake, defined in time units that take the product information and active ingredient into account in order to guarantee an average concentration of the active ingredient in the patient that treats the symptoms. Mr. Müller therefore does not fall below a certain value, but also does not exceed a maximum value that would be a health risk.
  • Figure VI.5 shows a combination of vaporizer and oral intake. 5.1 shows the vaporizer in its active ingredient curve (DA), 5.2 shows the oral intake in the active ingredient curve (OR).
  • DA active ingredient curve
  • OR oral intake in the active ingredient curve
  • D is the zero value in the concentration. Between the zero value and the maximum value there is a medically desired average value for which a constant concentration must be maintained over a desired period of time.
  • Mr. Müller receives a vaporizer, which is of course connected to the database.
  • This vaporizer product is set up by the doctor via the database.
  • the vaporizer vaporizes the product based on the stored data and releases the active ingredient prescribed by the doctor in the prescribed concentration.
  • the active ingredient takes effect after 20 minutes and lasts for around 4 hours.
  • Mr. Müller takes this dose 1 DA /5.1 at 9:00 a.m. by inhalation.
  • Müller takes the dose 1 OR /5.2 at the same time, 9:00 a.m., but orally.
  • the dose inhaled at 9:00 a.m. takes effect after about 20 minutes and lasts for 4 hours.
  • the dose taken orally takes effect after 4 hours and lasts for about 4 to 8 hours. This means that Mr. Müller has a constant dose for at least the next 8 hours until 5:00 p.m.
  • the dosage is now repeated with the same amount and with the same product combination of oral medication and inhalation (dose 2).
  • Table 2 Type of application and mode of action: onset and duration of action of medical cannabis when administered inhalatively and orally
  • the present invention is described in more detail below in the form of particularly preferred embodiments, specifically with regard to a) the revolver mechanism b) the device referred to here as "MediGuard", which communicates via the database in interaction between patient and doctor, whereby the database, the cloud are connected to the smoking device and the measuring device.
  • the database has knowledge of all specified positions as well as the product / active ingredient itself. Everything can be set, adapted, read, stored and monitored via the positions.
  • the digital setting via a digital device, preferably a cell phone or tablet, which communicates with the device and digitally receives knowledge of the products.
  • the revolver mechanism b) the device referred to here as "MediGuard", which communicates via the database in interaction between patient and doctor, whereby the database, the cloud are connected to the smoking device and the measuring device.
  • the database has knowledge of all specified positions as well as the product / active ingredient itself. Everything can be set, adapted, read, stored and monitored via the positions.
  • the digital setting via a digital device, preferably
  • the revolver rotation mechanism is rotated clockwise or anti-clockwise into the various usable positions. At least one cartridge but also multiple cartridges are possible, which can be rotated in a uniform direction into at least one smoking position, here also multiple possible in order to mix flavors in a deliberate and defined way. Viewing windows or digital transmission to inform which flavors are being smoked are available. b) the "MediGuard"
  • the MediGuard is a defined smoking device with a digital reader for inserting a product cartridge that is defined by a digital sensor (RFID/QR).
  • RFID/QR digital sensor
  • This smoking device is assigned to a consumer/patient.
  • This smoking device is designed to identify the inserted product cartridge.
  • the consumer/patient is created with his/her patient data/physical/chemical properties/illnesses in an app or cloud or similar database.
  • the product cartridge with its properties and all product information on treatment, chemical and physical properties is stored in the same database/app/cloud.
  • a chemical and physical data measuring device assigned to the consumer/patient, is digitally connected to the smoking device and to the cloud/app/database.
  • This measuring device is designed to measure the chemical and physical data of the consumer/patient. The Measurements individually as well as in connection with the smoke device are communicated to the cloud/app/database.
  • the database is designed in such a way that the positions of the smoking device, the measuring device, the product cartridge and the consumer/patient are stored. All data of the created positions communicate with the database and the stored instructions for consumption/smoking/medical purposes.
  • the product cartridge is stored in its chemical and physical properties, its ingredients and active ingredients.
  • the product used is then digitally read by the digital sensor of the smoking device via the cloud, and the smoking device stores all information about the product as well as the intended dosage of consumption.
  • Consumption is designed and adjustable in that the product is known as follows: in its ingredient in effect, percentage and physical / chemical properties, in its release in the dosage of the active ingredient through temperature-dependent exposure.
  • This known dose is then compared with the user/patient data and prescribed dosage.
  • This dosage is adjusted to the smoking device and the permitted intake/consumption measured by time, duration of consumption, strength of consumption/intake in relation to the knowledge of the dosage released by exposure to a certain temperature.
  • the release of the dosage by temperature is stored for each temperature (linear, exponential) in order to allow dosing by physical adjustment at the To deposit and allow smoking device, when is consumption, how much airflow may be consumed, what amount and/or time of airflow/outlet is given.
  • the smoking device is set digitally using information stored in the database, adapted to the temperature and the known release of the active ingredient, as well as the digitally set release of the consumption at a specific time and the amount consumed by controlling the airflow and the time of the airflow.
  • This consumption can also be set at a specific time, for example morning / noon / evening.
  • this prescription can be guaranteed in terms of active ingredient and intake through the described concept, the behavior of the consumer/patient can be monitored, even at the same time as consumption/during consumption by measuring their chemical and physical data via the measuring device, which simultaneously stores the measured data in the database of the smoking device.
  • This has the advantage of being able to adapt the medical prescription based on the data received. It is also possible to collect the data worldwide via a database in order to optimize the medical application. c) digital adjustment via a digital device
  • a smoking device in particular electronic cigarettes such as vapes and the like, are equipped or can be equipped with at least one identifiable product cartridge, which can be digitally identified via sensor technology.
  • This smoking device digitally connected to another digital device (mobile phone, tablet or similar), is designed so that the information about the product cartridges used is communicated to this digital device. This can preferably be read out and displayed in an associated app.
  • the display defines the product cartridges. It is possible to select or deselect the product cartridges on the display.
  • the display opens the Possibility to mix each product cartridge with each other.
  • the display offers the possibility to set each individual product cartridge in percentage (via a slider, preferably from left to right) to set the strength (via digitally attached minus and plus signs or similar). These specified and selected settings are then passed on from the mobile device to the smoking device and implemented as instructed
  • the implementation of the digital setting and the adjustment of the strength of consumption can work through different heating elements, and/or by increasing or decreasing the temperature of the individual pressure cartridges, and/or by regulating the aerosol/smoke emitted by your product cartridge, and/or by mixing the flavors in a collecting tank designed for this purpose, in which the added flavors, selected in their quantity, are mixed and vaporized.
  • a product cartridge is inserted into the vaporizer / smoking device, the filling quantity of which (liquid / solid) is known. Furthermore, the proportion of active ingredient is known, preferably but not exclusively THC / CBD,
  • a temperature is set within a recommended temperature range, preferably but not exclusively between 180 °C and 210 °C.
  • Marijuana flower 2 g ground, with a known THC content of 5% (5 mg) is filled into the product cartridge.
  • This product cartridge is inserted into the vaporizer/smoking device and vaporized/burned at a set temperature of 175 °C. The time unit of combustion/evaporation until the product used in the product cartridge is completely consumed is measured.
  • the product cartridge contains 2 g, which corresponds to 2 * 5 mg of active ingredient. Total active ingredient in quantity 10 mg.
  • the complete consumption of the used filling quantity (marijuana flower) when vaporizing/smoking is 100 seconds. This means that an active ingredient content of 0.1 mg per second can be defined.
  • the inserted product cartridge with a known product preferably but not exclusively cannabis / THC / CBD
  • a known product preferably but not exclusively cannabis / THC / CBD
  • This air flow is measured using a sensor device according to the respective active ingredient: proportion and resulting amount of the active ingredient. This proportion is measured simultaneously in a unit of time.
  • the resulting absorbable active ingredient content in the defined air flow can later be used to adjust the patient's dose.
  • cannabis can be inhaled or taken orally. Medical cannabis as a whole flower should always be preferred by inhaling it by smoking or vaporizing it with a vaporizer, as this does not produce any potentially harmful substances.
  • THC the main active ingredient in cannabis, is found in a pharmacologically inactive form. In order to convert the THC-A into an active, effective form, the flowers must be heated.
  • Established indications for medical cannabis include chronic - especially neuropathic - pain, spasticity in MS, loss of appetite, nausea and vomiting.
  • Evidence of positive effects ranges from neurological (spasticity and pain of various causes, hyperkinetic movement disorders) to internal (arthritis, ulcerative colitis, Crohn's disease) and psychiatric illnesses (depression, anxiety disorders, post-traumatic stress disorder, ADHD, sleep disorders), epilepsy, Tourette's, etc.
  • the vaporizer/smoking device is also connected digitally (for example via Wi-Fi/Bluetooth or similar).
  • Wi-Fi/Bluetooth wireless fidelity
  • the patient is explicitly monitored when consuming the active ingredient. For example, blood pressure goes up, body temperature rises, monitoring of blood sugar levels/insulin, especially for diabetics. Based on this data, the doctor has the option of re-adjusting and adjusting the patient.
  • Cannabis should always be dosed gradually at first.
  • the initial dose of flowers should be 0.25 g to a maximum of 1 g.
  • the dose can be increased by around 25 mg to 100 mg of cannabis (corresponding to 2.5 mg to 5 mg THC depending on the variety) every 1 to 3 days.
  • the maximum daily dose is 3 g and should not be exceeded. Close consultation with the doctor is always required for individual dosage.
  • the intake of cannabis extracts and the exact dosage depend on the active ingredient content of the extract, the amount and concentration of the active ingredient released by the vaporizer/smoking device and the patient's symptoms, as well as general information about the patient, for example, but not limited to, gender, age, weight, medical history.
  • treatment should begin with a lower dosage and slowly increase over a period of several weeks.
  • treatment of Tourette syndrome with medical cannabis can be started with a low THC dose of 2.5 mg to 5 mg per day and gradually increased to a dose of 10 mg to 20 mg per day depending on effectiveness and tolerability.
  • the dose should be divided into two to three doses per day.
  • THC tetrahydrocannabinol
  • CBD cannabidiol
  • our invention makes it possible to store the increase in dose in a defined time window, adapted to the patient's information (age, gender, weight, etc.) in the database.
  • These are precisely defined by the fixed parameters in dose, intake time, duration and increase in dose according to the specifications in the database.
  • Mr. Müller receives his vaporizer with product cartridge
  • Vaporizer the prescribed product cartridge and the patient's intake instructions are stored in the doctor's database
  • Day 2 5mg Day 3 5mg Day 4 5mg Day 5 2 x 5mg (morning/evening) from day 15 2 x 10 mg (morning and evening) Day 15: Feedback from monitoring device on patient: Blood pressure too high
  • Database is read via Kl and patient data, findings and dosage settings are used to optimize Active ingredient mixture at least two cartridges
  • Mixed combinations of active ingredients can also be offered on at least two product cartridges and, depending on the location, study location and monitoring of the database, can be adapted individually to the patient, as well as the location and findings.
  • CBD and THC mixture have been proven to alleviate symptoms.
  • the number of studies is currently small and weak.
  • Our innovation can simplify various studies and initiate them worldwide by using artificial intelligence to evaluate the information fed into the database by various hospitals and doctors around the world.
  • the data on dosage and indication can be continuously improved on a patient-specific and/or symptom- and diagnosis-specific basis and patients can be offered the best medication and dosage.
  • a product cartridge with a known active ingredient release in combination with the vaporizing/smoking device is used with CBD.
  • a second product cartridge with a known active ingredient release in combination with the vaporizing/smoking device is used with THC.
  • the doctor can manually adjust different dosages or artificial intelligence can divide different studies into study groups and determine the dosages for each cartridge.
  • the data collected from this on well-being, relief of symptoms, etc. are fed into the database directly via the patient and/or via the hospital/doctors.
  • Another possibility for improvement, reduction, symptom control and medical indication is the 24-hour monitoring of the patient with the said measuring device.
  • This measuring device is digitally connected to the vaporizer and simultaneously via this or via mobile phone or directly to the database.
  • the measurement involves monitoring physical and/or chemical patient values to enable timely medication.
  • This early warning has the advantage of allowing the active ingredient to alleviate the symptoms to be consumed in advance, preferably by inhalation due to its faster effectiveness.
  • the patient Mr. Müller can receive his already set dose (see above) in advance. This can be done via a warning signal function, e.g. vibration of the bracelet.
  • a warning signal function e.g. vibration of the bracelet.
  • the release in early warnings is stored in the database and allows consumption outside of the specified dosage and intake instructions.
  • a medium, medical dosage can be set to achieve a symptom-relieving / alleviating mean value in the patient's blood
  • inhalation is the maximum release of the active ingredient after 20 minutes, duration of effect 2 to 3 hours.
  • oral administration the maximum release of the active ingredient is 2 to 4 hours and lasts 4 to 8 hours. In this way, an overlapping average can be achieved from the combination, since the effect of inhalation ends when the effect of the oral administration reaches its maximum.
  • the correct temperature setting of the vaporizer is another important point in vaporization.
  • a low temperature setting has a completely different effect than a high temperature. This is because the active ingredients contained evaporate at different temperatures.
  • THC the main active ingredient of the cannabis plant with a euphoric, pain-relieving and relaxing effect, evaporates from around 160 °C.
  • the second most common active ingredient, CBD which has an anti-anxiety and muscle-relaxing effects, has its boiling point at 160 °C to 180 °C.
  • the sedative and antibiotic CBN evaporates at 186 °C, while the pain-relieving THC-V only evaporates at 220 °C, which is almost no longer evaporation, but rather partial oxidation.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Business, Economics & Management (AREA)
  • Business, Economics & Management (AREA)
  • Databases & Information Systems (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un dispositif intelligent pour adapter la consommation de substances en fonction du consommateur, comprenant : un dispositif pour la réception, l'identification et le traitement d'une substance utilisée à consommer, au moins une substance utilisée à consommer, qui est identifiable de manière univoque par une caractéristique sensorielle, comme un code QR ou une puce de capteur, au moins une unité mobile portée côté consommateur et/ou près du corps, au moins une communication réseau sans fil entre toutes les unités portées par les utilisateurs, au moins une connexion réseau sans fil à un serveur de données central ou décentralisé pour l'échange des données acquises côté consommateur, au moins une interface pour le personnel médical spécialisé pour évaluer les données acquises côté consommateur. Cette invention concerne en outre un dispositif de formation d'aérosols.
PCT/IB2024/055904 2023-06-15 2024-06-17 Dispositif intelligent pour adapter numériquement l'état de consommation d'une substance Pending WO2024257066A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE102023115606.3 2023-06-15
DE102023115606 2023-06-15
DE102023117160.7 2023-06-29
DE102023117160 2023-06-29
DE102023117117 2023-06-29
DE102023117117.8 2023-06-29
DE102023121145.5 2023-08-08
DE102023121145 2023-08-08

Publications (2)

Publication Number Publication Date
WO2024257066A2 true WO2024257066A2 (fr) 2024-12-19
WO2024257066A3 WO2024257066A3 (fr) 2025-02-06

Family

ID=91924030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055904 Pending WO2024257066A2 (fr) 2023-06-15 2024-06-17 Dispositif intelligent pour adapter numériquement l'état de consommation d'une substance

Country Status (1)

Country Link
WO (1) WO2024257066A2 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2989912T3 (pl) * 2014-09-01 2020-01-31 Fontem Holdings 1 B.V. Elektroniczne urządzenie do palenia
US10405580B2 (en) * 2016-07-07 2019-09-10 Altria Client Services Llc Mechanically-adjustable e-vaping device flavor assembly
US11019847B2 (en) * 2016-07-28 2021-06-01 Rai Strategic Holdings, Inc. Aerosol delivery devices including a selector and related methods
US10779576B2 (en) * 2017-05-24 2020-09-22 VMR Products, LLC Flavor disk
WO2019157208A1 (fr) * 2018-02-08 2019-08-15 Optimist Inhaler LLC Éléments de sécurité pour inhalateur doseur électronique
CN113347896B (zh) * 2018-07-23 2025-01-07 健康洞察技术有限公司 用于分析和控制可消耗介质配量信息的系统
CN114096172A (zh) * 2019-02-01 2022-02-25 埃克索运营公司 汽化设备、系统和方法
WO2021188689A1 (fr) * 2020-03-17 2021-09-23 The Green Labs Group Inc. Dosage précis de contenu d'un vaporisateur
KR102490572B1 (ko) * 2020-09-23 2023-01-19 주식회사 케이티앤지 에어로졸 생성 장치

Also Published As

Publication number Publication date
WO2024257066A3 (fr) 2025-02-06

Similar Documents

Publication Publication Date Title
US20240050397A1 (en) Low dose therapeutic treatment
US20220211958A1 (en) Methods, devices and systems for pulmonary delivery of active agents
KR102634014B1 (ko) 활성제의 폐 전달을 위한 방법, 디바이스 및 시스템
AU2025200462A1 (en) Methods, Devices And Systems For Pulmonary Delivery Of Active Agents
DE69918333T2 (de) SYSTEM ZUR UNTERSTüTZUNG EINER MEDIZINISCHEN SELBSTBEHANDLUNG,WELCHE EINE MEHRZAHL VON SCHRITTEN UMFASST
CN106573123B (zh) 用于活性剂的肺部递送的方法、装置及系统
DE69225604T2 (de) Inhalator mit feedback für den patienten sowie für medizinisches personal
JP7265730B2 (ja) ユーザインターフェース装置
US20250157614A1 (en) Substance delivery planning system
AT501560A1 (de) Verwendung von kräuterzigaretten
WO2024257066A2 (fr) Dispositif intelligent pour adapter numériquement l'état de consommation d'une substance
Henningfield et al. Intravenous cocaine self-administration by human volunteers: second-order schedules of reinforcement
DE102007026752A1 (de) Vorrichtung zur Aufbewahrung und Applikation von Wirkstoffen
AT513652B1 (de) Vorrichtung und Verfahren zur Herstellung, Dosierung und Verpackung von Arzneimitteln
WO2016177834A2 (fr) Préparation pour la vitalisation et la sédation pharmacologiques ou combinaison chronologique de celles-ci au moyen d'une cinétique de libération commandée en temps et dispositif pour l'utilisation de la préparation
Griffiths Helping people to stop smoking
Lee et al. Effect of Aromatherapy on Postoperative Nausea & Vomiting and satisfaction in patients who have undergone Laparoscopic Hystrectomy
Dansak and Appetite Stimulant